Type I interferons have opposing effects during the emergence and recovery phases of colitis

Isabella Rauch, Eva Hainzl, Felix Rosebrock, Susanne Heider, Clarissa Schwab, David Berry, Dagmar Stoiber, Michael Wagner, Christa Schleper, Alexander Loy, Tim Urich, Mathias Müller, Birgit Strobl, Lukas Kenner, Thomas Decker

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The contribution of the innate immune system to inflammatory bowel disease (IBD) is under intensive investigation. Research in animal models has demonstrated that type I interferons (IFN-Is) protect from IBD. In contrast, studies of patients with IBD have produced conflicting results concerning the therapeutic potential of IFN-Is. Here, we present data suggesting that IFN-Is play dual roles as regulators of intestinal inflammation in dextran sodium sulfate (DSS)-treated C57BL/6 mice. Though IFN-Is reduced acute intestinal damage and the abundance of colitis-associated intestinal bacteria caused by treatment with a high dose of DSS, they also inhibited the resolution of inflammation after DSS treatment. IFN-Is played an anti-inflammatory role by suppressing the release of IL-1β from the colon MHC class II+ cells. Consistently, IL-1 receptor blockade reduced the severity of inflammation in IFN-I receptor-deficient mice and myeloid cell-restricted ablation of the IFN-I receptor was detrimental. The proinflammatory role of IFN-Is during recovery from DSS treatment was caused by IFN-I-dependent cell apoptosis as well as an increase in chemokine production and infiltrating inflammatory monocytes and neutrophils. Thus, IFN-Is play opposing roles in specific phases of intestinal injury and inflammation, which may be important for guiding treatment strategies in patients.

Original languageEnglish (US)
Pages (from-to)2749-2760
Number of pages12
JournalEuropean Journal of Immunology
Volume44
Issue number9
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Interferon Type I
Colitis
Dextran Sulfate
Inflammatory Bowel Diseases
Inflammation
Therapeutics
Interleukin-1 Receptors
Myeloid Cells
Interleukin-1
Inbred C57BL Mouse
Chemokines
Monocytes
Immune System
Colon
Neutrophils
Anti-Inflammatory Agents
Animal Models
Apoptosis
Bacteria
Wounds and Injuries

Keywords

  • Colitis
  • Inflammation
  • Interferons
  • Interleukin-1
  • Microbiota

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Type I interferons have opposing effects during the emergence and recovery phases of colitis. / Rauch, Isabella; Hainzl, Eva; Rosebrock, Felix; Heider, Susanne; Schwab, Clarissa; Berry, David; Stoiber, Dagmar; Wagner, Michael; Schleper, Christa; Loy, Alexander; Urich, Tim; Müller, Mathias; Strobl, Birgit; Kenner, Lukas; Decker, Thomas.

In: European Journal of Immunology, Vol. 44, No. 9, 01.01.2014, p. 2749-2760.

Research output: Contribution to journalArticle

Rauch, I, Hainzl, E, Rosebrock, F, Heider, S, Schwab, C, Berry, D, Stoiber, D, Wagner, M, Schleper, C, Loy, A, Urich, T, Müller, M, Strobl, B, Kenner, L & Decker, T 2014, 'Type I interferons have opposing effects during the emergence and recovery phases of colitis', European Journal of Immunology, vol. 44, no. 9, pp. 2749-2760. https://doi.org/10.1002/eji.201344401
Rauch, Isabella ; Hainzl, Eva ; Rosebrock, Felix ; Heider, Susanne ; Schwab, Clarissa ; Berry, David ; Stoiber, Dagmar ; Wagner, Michael ; Schleper, Christa ; Loy, Alexander ; Urich, Tim ; Müller, Mathias ; Strobl, Birgit ; Kenner, Lukas ; Decker, Thomas. / Type I interferons have opposing effects during the emergence and recovery phases of colitis. In: European Journal of Immunology. 2014 ; Vol. 44, No. 9. pp. 2749-2760.
@article{b5b321f051b949808f0c8ff863e8d102,
title = "Type I interferons have opposing effects during the emergence and recovery phases of colitis",
abstract = "The contribution of the innate immune system to inflammatory bowel disease (IBD) is under intensive investigation. Research in animal models has demonstrated that type I interferons (IFN-Is) protect from IBD. In contrast, studies of patients with IBD have produced conflicting results concerning the therapeutic potential of IFN-Is. Here, we present data suggesting that IFN-Is play dual roles as regulators of intestinal inflammation in dextran sodium sulfate (DSS)-treated C57BL/6 mice. Though IFN-Is reduced acute intestinal damage and the abundance of colitis-associated intestinal bacteria caused by treatment with a high dose of DSS, they also inhibited the resolution of inflammation after DSS treatment. IFN-Is played an anti-inflammatory role by suppressing the release of IL-1β from the colon MHC class II+ cells. Consistently, IL-1 receptor blockade reduced the severity of inflammation in IFN-I receptor-deficient mice and myeloid cell-restricted ablation of the IFN-I receptor was detrimental. The proinflammatory role of IFN-Is during recovery from DSS treatment was caused by IFN-I-dependent cell apoptosis as well as an increase in chemokine production and infiltrating inflammatory monocytes and neutrophils. Thus, IFN-Is play opposing roles in specific phases of intestinal injury and inflammation, which may be important for guiding treatment strategies in patients.",
keywords = "Colitis, Inflammation, Interferons, Interleukin-1, Microbiota",
author = "Isabella Rauch and Eva Hainzl and Felix Rosebrock and Susanne Heider and Clarissa Schwab and David Berry and Dagmar Stoiber and Michael Wagner and Christa Schleper and Alexander Loy and Tim Urich and Mathias M{\"u}ller and Birgit Strobl and Lukas Kenner and Thomas Decker",
year = "2014",
month = "1",
day = "1",
doi = "10.1002/eji.201344401",
language = "English (US)",
volume = "44",
pages = "2749--2760",
journal = "European Journal of Immunology",
issn = "0014-2980",
publisher = "Wiley-VCH Verlag",
number = "9",

}

TY - JOUR

T1 - Type I interferons have opposing effects during the emergence and recovery phases of colitis

AU - Rauch, Isabella

AU - Hainzl, Eva

AU - Rosebrock, Felix

AU - Heider, Susanne

AU - Schwab, Clarissa

AU - Berry, David

AU - Stoiber, Dagmar

AU - Wagner, Michael

AU - Schleper, Christa

AU - Loy, Alexander

AU - Urich, Tim

AU - Müller, Mathias

AU - Strobl, Birgit

AU - Kenner, Lukas

AU - Decker, Thomas

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The contribution of the innate immune system to inflammatory bowel disease (IBD) is under intensive investigation. Research in animal models has demonstrated that type I interferons (IFN-Is) protect from IBD. In contrast, studies of patients with IBD have produced conflicting results concerning the therapeutic potential of IFN-Is. Here, we present data suggesting that IFN-Is play dual roles as regulators of intestinal inflammation in dextran sodium sulfate (DSS)-treated C57BL/6 mice. Though IFN-Is reduced acute intestinal damage and the abundance of colitis-associated intestinal bacteria caused by treatment with a high dose of DSS, they also inhibited the resolution of inflammation after DSS treatment. IFN-Is played an anti-inflammatory role by suppressing the release of IL-1β from the colon MHC class II+ cells. Consistently, IL-1 receptor blockade reduced the severity of inflammation in IFN-I receptor-deficient mice and myeloid cell-restricted ablation of the IFN-I receptor was detrimental. The proinflammatory role of IFN-Is during recovery from DSS treatment was caused by IFN-I-dependent cell apoptosis as well as an increase in chemokine production and infiltrating inflammatory monocytes and neutrophils. Thus, IFN-Is play opposing roles in specific phases of intestinal injury and inflammation, which may be important for guiding treatment strategies in patients.

AB - The contribution of the innate immune system to inflammatory bowel disease (IBD) is under intensive investigation. Research in animal models has demonstrated that type I interferons (IFN-Is) protect from IBD. In contrast, studies of patients with IBD have produced conflicting results concerning the therapeutic potential of IFN-Is. Here, we present data suggesting that IFN-Is play dual roles as regulators of intestinal inflammation in dextran sodium sulfate (DSS)-treated C57BL/6 mice. Though IFN-Is reduced acute intestinal damage and the abundance of colitis-associated intestinal bacteria caused by treatment with a high dose of DSS, they also inhibited the resolution of inflammation after DSS treatment. IFN-Is played an anti-inflammatory role by suppressing the release of IL-1β from the colon MHC class II+ cells. Consistently, IL-1 receptor blockade reduced the severity of inflammation in IFN-I receptor-deficient mice and myeloid cell-restricted ablation of the IFN-I receptor was detrimental. The proinflammatory role of IFN-Is during recovery from DSS treatment was caused by IFN-I-dependent cell apoptosis as well as an increase in chemokine production and infiltrating inflammatory monocytes and neutrophils. Thus, IFN-Is play opposing roles in specific phases of intestinal injury and inflammation, which may be important for guiding treatment strategies in patients.

KW - Colitis

KW - Inflammation

KW - Interferons

KW - Interleukin-1

KW - Microbiota

UR - http://www.scopus.com/inward/record.url?scp=84907828155&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907828155&partnerID=8YFLogxK

U2 - 10.1002/eji.201344401

DO - 10.1002/eji.201344401

M3 - Article

C2 - 24975266

AN - SCOPUS:84907828155

VL - 44

SP - 2749

EP - 2760

JO - European Journal of Immunology

JF - European Journal of Immunology

SN - 0014-2980

IS - 9

ER -